Targeted delivery of silver nanoparticles and alisertib: In vitro and in vivo synergistic effect against glioblastoma

Nanomedicine

Volumn 9, Issue 6, 2014, Pages 839-849

  Locatelli, Erica ^a   Naddaka, Maria ^a   Uboldi, Chiara ^b   Loudos, George ^c   Fragogeorgi, Eirini ^c   Molinari, Valerio ^a   Pucci, Andrea ^a   Tsotakos, Theodoros ^c   Psimadas, Dimitrios ^c   Ponti, Jessica ^b   Franchini, Mauro Comes ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b JOINT RESEARCH CENTRE   (Italy)

^c UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

alisertib; cancer; glioblastoma; nanoprecipitation; organic coating; polymeric nanoparticle; radiolabeling; silver nanoparticle; toxicity; tumor reduction

Indexed keywords

ALISERTIB; CHLOROTOXIN; GELATINASE A; NANOCOMPOSITE; PEPTIDE DERIVATIVE; POLYMER; POVIDONE; SILVER NANOPARTICLE; TECHNETIUM 99M; TRYPAN BLUE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; NANOPARTICLE; PYRIMIDINE DERIVATIVE; SCORPION VENOM; SILVER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL LINE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHESIS; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; DRUG POTENTIATION; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZEPINES; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; MICE; NANOPARTICLES; POLYMERS; PYRIMIDINES; SCORPION VENOMS; SILVER; TISSUE DISTRIBUTION;

EID: 84903781961     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.1     Document Type: Article

References (44)

1. Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocyticglioma: genetics, biology, and paths to treatment. Genes Dev. 21, 2683-2710 (2007). (Pubitemid 350070717)
2. Siegel R, Naishadham D, Jemal A. Cancer statistic. CA Cancer. J. Clin. 62, 10-29 (2012).
3. Weingart J, Grossman SA, Carson KA et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS Consortium Trial. J. Clin. Oncol. 25(4), 399-404 (2007). (Pubitemid 350002988)
4. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005). (Pubitemid 40349501)
5. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic KJY, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology 12(3), 233-242 (2010).
6. Addeo R, Caraglia M, De Santi S et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J. Neurooncol. 102, 417-424 (2011).
7. Kohler BA, Ward E, McCarthy BK et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl Cancer Inst. 103, 714-736 (2011).
8. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotech. 24, 1211-1217 (2006). (Pubitemid 44564760)
9. Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine 1, 101-109 (2005). (Pubitemid 43963616)
10. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 1, 193-212 (2005). (Pubitemid 43963632)
11. Freitas RA. What is nanomedicine? Nanomedicine 1, 2 (2005).
12. Kreuter J. Nanoparticles as drug delivery systems. In:Encycolpedia of Nanoscience and Nanotechnology (Volume 7) . Nalwa HS (Ed.). American Scientific Publishers, CA, USA, 161-180 (2004).
13. Lamprecht A, Ubrich N, Yamamoto H et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299, 775-781 (2001).
14. Gregoriadis G. Drug entrapment in liposomes. FEBS Lett. 36, 292-296 (1973).
15. Hrkach J, Von Hoff D, Ali MM et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128 (2012).
16. Gu F, Zhang L, Teply BA et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105, 2586-2591 (2008). (Pubitemid 351520557)
17. Locatelli E, Comes Franchini M. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties and nanomedical applications as drug delivery system. J. Nanop. Res. 14, 1316 (2012).
18. Locatelli E, Broggi F, Ponti J, Marmorato P, Lena S, Comes Franchini M. Lipophilic silver nanoparticles and their polymeric entrapment into targeted-PEG-based micelles for the treatment of glioblastoma. Adv. Healthcare Mat. 1, 342-347 (2012).
19. Deshane J, Garner CG, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J. Biol. Chem. 278, 4135-4144 (2003). (Pubitemid 36801150)
20. Veiseh O, Sun C, Gunn J et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett. 5, 1003-1008 (2005). (Pubitemid 40925409)
21. Psimadas D, Baldi G, Ravagli C et al. Preliminary evaluation of a 99mTc labeled hybrid nanoparticle bearing a cobalt ferrite core. J. Biomed. Nanotechnol. 8(4), 575-585 (2012).
22. Psimadas D, Bouziotis P, Georgoulias P, Valotassiou V, Tsotakos T, Loudos G. Radiolabeling approaches of nanoparticles with 99mTc. Contrast Media Mol. Imaging 8(4), 333-339 (2013).
23. Loudos G, Majewski S, Wojcik R et al. Performance evaluation of a dedicated camera suitable for dynamic radiopharmaceuticals evaluation in small animals. IEEE Trans. Nucl. Sci. 54(3), 454-460 (2007). (Pubitemid 46956983)
24. Gentili D, Ori G, Comes Franchini M. Double phase transfer of gold nanorods for surface functionalization and entrapment into PEG-based nanocarriers. Chem. Comm. 39, 5874 (2009).
25. Ponti J, Lemor R, Fournelle M, Broggi F, Locatelli E, Comes Franchini M. Polymeric entrapped thiol-coated gold nanorods: cytotoxicity and suitability as molecular optoacoustic contrast agent. J. Mat. Chem. 20, 10908-10914 (2010).
26. Bonini BF, Camaggi CM, Comes Franchini M et al. Design and synthesis of novel 3, 4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas. Eng. J. Med. Chem. 45, 2024-2033 (2010).
27. Liu J, Sonshine D, Shervani S, Hurt RH. Controlled release of biologically active silver from nanosilver surfaces. ACS Nano 4, 6903-6913 (2010).
28. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Ann. Rev. Biomed. Eng. 14, 1-16 (2012).
29. Nemmar A, Hoylaerts MF, Hoet PH et al. Ultrafine particles affect experimental thrombosis in an In vivo hamster model. Am. J. Respir. Crit. Care Med. 166, 998-1004 (2002). (Pubitemid 35193233)
30. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid-nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875 (2010).
31. Matulonis UA, Sharma S, Ghamande S et al. Phase II study of MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol. Oncol. 127(1), 63 (2012).
32. Cervantes A, Elez E, Roda D et al. Phase I pharmacokinetic/ pharmacodynamic study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 18(17), 4764-4774 (2012).
33. Dees EC, Cohen RB, von Mehren M et al. Phase I study of aurora a kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin. Cancer Res. 18(17), 4775-4784 (2012).
34. Jeyaraj M, Sathishkumar G, Sivanandhan G et al. Biogenic silver nanoparticles for cancer treatment: an experimental report. Colloids Surf. B Biointerfaces 106, 86-92 (2013).
35. Guo D, Zhu L, Huang Z et al. Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions. Biomaterials 34(32), 7884-7894 (2013).
36. Wu Q, Cao H, Luan Q et al. Biomolecule-assisted synthesis of water-soluble silver nanoparticles and their biomedical applications. Inorg. Chem. 47, 5882-5888 (2008).
37. Asharani PV, Wu YL, Gong Z, Valiyaveettil S. Toxicity of silver nanoparticles in zebrafish models. Nanotechnology 19, 255102-255110 (2008).
38. Eckelman WC, Richards P, Meinken G. The chemical state of 99mTc in biomedical products. II. The chelation of reduced technetium with DTPA. J. Nucl. Med. 13, 577-581 (1972).
39. Rattat D, Terwinghe C, Verbruggen A. Comparison of classic 99mTc-DTPA, 99mTc (CO) 3-DTPA and 99mTc (CO) 2 (NO)-DTPA. Tetrahedron 61(40), 9563-9566 (2005).
40. Psimadas D, Oliveira H, Thevenot J et al. Polymeric micelles and vesicles: biological behavior evaluation using radiolabeling techniques. Pharm. Dev. Technol. 19(2), 189-193 (2014).
41. Caraglia M, Longo L, Salzano G et al. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain. Mol. Pharmaceutics 10, 1111-1118 (2013).
42. Pratsinis A, Hervella P, Leroux JC, Pratsinis SE, Sotiriou GA. Toxicity of silver nanoparticles in macrophages. Small 9(15), 2576-2584 (2013).
43. Kittler S, Greulich C, Diendorf J, Koeller M, Epple M. Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions. Chem. Mater. 22, 4548-4554 (2010).
44. Xiu ZM, Zhang QB, Puppala HL, Colvin VL, Alvarez PJJ. Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett. 12, 4271-4275 (2012).